CTS Corporation Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by CTS Corporation on November 5, 2025. The filing reports a corporate governance event effective November 5, 2025, involving the expansion of the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on board composition changes and does not contain financial performance data.
Material Changes
- Board Expansion: The Board of Directors increased its size from seven to eight members.
- New Director Election: Kimberly MacKay was elected to fill the resulting vacancy.
- Director Background: Ms. MacKay currently serves as SVP, General Counsel, and Corporate Secretary of West Pharmaceutical Services, Inc.
- Committee Assignments: Ms. MacKay will serve on the Nominating, Governance and Sustainability Committee and the Technology and Transactions Committee.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding business operations. No new risks or contingencies were disclosed. The filing confirms there are no related person transactions requiring disclosure under Item 404(a) of Regulation S-K and no undisclosed arrangements regarding Ms. MacKay's selection.
Investor Verification Checklist
- Verify the effective date of the board expansion (November 5, 2025).
- Confirm Ms. MacKay's compensation structure aligns with existing non-employee director terms disclosed in the March 28, 2025, Schedule 14A Proxy Statement.
- Review the Indemnification Agreement form previously disclosed on February 18, 2015.
- Check the press release (Exhibit 99.1) for additional context on the director election.